Recordati

Recordati Rare Diseases UK is part of the Recordati group, an international pharmaceutical group established in 1926 and listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals.

Head-quartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. A field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under licence, in a number of therapeutic areas including a specialised business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licences for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases.

Revenue from drugs for rare diseases constitute about 20% of Recordati’s revenues.